Payment overview · 2025
General Payments
$229.40
12 reported records · 6 companies
Healthcare provider profile · identity verified
Stacy J Burns, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1427243740
Verified facts
What the public records show
CMS Open Payments records show Stacy J Burns, MD received $229.40 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $100.01 | 43.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.08 | 23.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.00 | 9.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.70 | 8.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.18 | 8.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.43 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.40 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $100.01 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.08 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
182 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
147 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
114 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 600 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 520 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 509 | 118 |
| Losartan Potassium | Losartan Potassium | 382 | 93 |
| Omeprazole | Omeprazole | 290 | 78 |
| Furosemide | Furosemide | 272 | 67 |
| Gabapentin | Gabapentin | 266 | 68 |
| Sertraline Hcl | Sertraline Hcl | 259 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 61 |
| Alprazolam | Alprazolam | 202 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 53 |
| Lisinopril | Lisinopril | 197 | 55 |
| Famotidine | Famotidine | 191 | 62 |
| Metformin Hcl | Metformin Hcl | 189 | 47 |
| Eliquis | Apixaban | 182 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 48 |
| Simvastatin | Simvastatin | 166 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 43 |
| Ozempic | Semaglutide | 147 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 40 |
| Telmisartan | Telmisartan | 142 | 32 |
| Jardiance | Empagliflozin | 136 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 34 |
| Trazodone Hcl | Trazodone Hcl | 126 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 122 | 28 |
| Ezetimibe | Ezetimibe | 119 | 32 |
| Clonazepam | Clonazepam | 115 | 25 |
| Rybelsus | Semaglutide | 114 | 19 |
| Carvedilol | Carvedilol | 113 | 28 |
| Allopurinol | Allopurinol | 112 | 29 |
| Tramadol Hcl | Tramadol Hcl | 107 | 33 |
| Spironolactone | Spironolactone | 106 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 39 |
| Metformin Hcl Er | Metformin Hcl | 102 | 29 |
| Potassium Chloride | Potassium Chloride | 100 | 35 |
| Prednisone | Prednisone | 99 | 75 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 21 |
| Farxiga | Dapagliflozin Propanediol | 96 | 19 |
| Benazepril Hcl | Benazepril Hcl | 90 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 27 |
| Lorazepam | Lorazepam | 90 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 78 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 20 |
| Synthroid | Levothyroxine Sodium | 84 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 21 |
| Alendronate Sodium | Alendronate Sodium | 80 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Pregabalin | Pregabalin | 79 | 16 |
| Valsartan | Valsartan | 72 | 20 |
| Glimepiride | Glimepiride | 71 | 17 |
| Atenolol | Atenolol | 68 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 21 |
| Mounjaro | Tirzepatide | 64 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Diazepam | Diazepam | 63 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 19 |
| Cephalexin | Cephalexin | 57 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 16 |
| Meloxicam | Meloxicam | 54 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 19 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | 22 |
| Klor-Con M20 | Potassium Chloride | 50 | 18 |
| Methocarbamol | Methocarbamol | 50 | 15 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 11 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 41 |
| Ramipril | Ramipril | 43 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 29 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Myrbetriq | Mirabegron | 39 | 13 |
| Torsemide | Torsemide | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 31 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Zaleplon | Zaleplon | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Cefdinir | Cefdinir | 34 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 21 |
| Colchicine | Colchicine | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Klor-Con M10 | Potassium Chloride | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alprazolam Er | Alprazolam | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.40 · 12 records | Novo Nordisk Inc | CAMZYOS, EVENITY, General - Pain Management, INSPIRE, PROLIA, QULIPTA, UBRELVY, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error